Previous 10 | Next 10 |
2024-03-18 13:15:02 ET Needham analyst issues BUY recommendation for AUTL on March 18, 2024 12:01PM ET. The previous analyst recommendation was Buy. AUTL was trading at $5.99 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst...
2024-03-15 05:23:07 ET Autolus Therapeutics plc (AUTL) Q4 2023 Earnings Conference Call March 14, 2024, 08:30 AM ET Company Participants Olivia Manser - Investor Relations Christian Itin - Chief Executive Officer Rob Dolski - Chief Financial Officer Confere...
2024-03-14 07:02:41 ET More on Autolus Therapeutics BioNTech Buys Into Autolus' Cell Therapy Tech - Why I Expect A Full Acquisition In Time Autolus Upgrades Leadership And Faces CAR-T Approval SA Analysts Comment On FDA Seeking Boxed Warning For CAR-T Cancer Therapie...
AIA Group Limited ADR (AAGIY) is expected to report for Q4 2023 Bank of Georgia Group Plc (BDGSF) is expected to report for quarter end 2023-12-31 SecureWorks Corp. (SCWX) is expected to report $-0.15 for Q4 2024 Acacia Research Corporation (ACTG) is expected to report for quarter end...
Announced strategic collaboration and equity investment from BioNTech for aggregate proceeds of $250 million upfront, plus underwritten offering of ADSs for $350 million, for gross proceeds of $600 million received in February 2024 Submitted a Biologics License Application (BLA) for obeca...
2024-03-13 12:32:48 ET More on Autolus Therapeutics BioNTech Buys Into Autolus' Cell Therapy Tech - Why I Expect A Full Acquisition In Time Autolus Upgrades Leadership And Faces CAR-T Approval SA Analysts Comment On FDA Seeking Boxed Warning For CAR-T Cancer Therapie...
LONDON, March 12, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that following the most recent GMP inspection by the MHRA in February 2024, Autolus’ N...
LONDON, March 11, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced a publication in Blood Cancer Journal entitled ‘ Dual T-cell constant β ...
LONDON, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that it will release its fourth quarter and full year 2023 results and operational highlights ...
2024-02-22 19:04:44 ET Summary BioNTech and Autolus have announced a strategic alliance to advance their autologous CAR-T programs toward market authorization. BioNTech, known for its COVID-19 vaccine, is diverting its focus back to oncology and has a diverse, but immature pipelin...
News, Short Squeeze, Breakout and More Instantly...
Autolus Therapeutics plc Company Name:
AUTL Stock Symbol:
NASDAQ Market:
Autolus Therapeutics plc Website:
LONDON, July 26, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its second quarter 2024 financial results and operational highlights befo...
The majority of patients that responded to obe-cel showed durable responses with the potential for a long-term plateau of survival outcomes 40% patients are in ongoing remission without subsequent stem cell transplant (SCT) or other intervention Ongoing CAR T persistence was associated wi...